Relativity Shareholders Approve Merger with Instinct Bio Technical
Relativity 股東批准與 Instinct Bio Technical 的合併案
On March 24, 2026, shareholders of Relativity Acquisition Corp.
2026年3月24日，Relativity Acquisition Corp.
(OTC: ACQC) officially voted to approve a business combination with the Japanese firm Instinct Bio Technical Company Inc.
(OTC: ACQC) 的股東正式投票通過了與日本Instinct Bio Technical Company Inc.
This merger, valued at approximately $242 million, allows the regenerative medicine company to go public and transition its shares to the NASDAQ exchange under the ticker symbol "BIOT."
的業務合併案。
Founded in 2017, Instinct Bio Technical distinguishes itself through a vertically integrated business model that controls the entire lifecycle of its stem cell-based skincare and wellness products.
這項價值約2.42億美元的合併案，讓這家再生醫學公司得以公開上市，並將其股票轉移至NASDAQ交易所，股票代號為「BIOT」。
Tomoki Nagano, the founder of the company, will lead the combined entity as it aims for international expansion.
Instinct Bio Technical成立於2017年，其特點在於擁有垂直整合的商業模式，能控管其幹細胞護膚與健康產品的整個生命週期。
The firm plans to use the capital raised from this public listing to scale its operations, including building new facilities in Japan and introducing its unique clinic model into markets like Malaysia and Indonesia.
公司創辦人Tomoki Nagano將領導合併後的實體，目標是進行國際擴張。
While the merger is expected to close in the coming weeks, the successful shareholder vote signifies a major step toward the company's goal of becoming a global leader in the stem cell industry.
這筆交易標誌著該領域的重要里程碑，因其在高端再生科學與不斷成長的消費者健康市場之間搭建了橋樑。
